Thus, these data suggest that CV-1 treatment induces a systemic antitumor response in the presence of tumor cell-intrinsic IFN-I signaling, and this response is effective on IFNAR1 KO tumors; IFNAR1 deficiency in tumor cells does not influence the effector T cell killing function at the effector phase. The gene discussed is IFNAR1; the disease is neoplasm.